PlainRecalls
FDA Drug Moderate Class II Terminated

Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.

Reported: September 2, 2020 Initiated: August 14, 2020 #D-1533-2020

Product Description

Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.

Reason for Recall

Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.

Details

Units Affected
97,890 vials
Distribution
Nationwide in the U.S.
Location
Cherry Hill, NJ

Frequently Asked Questions

What product was recalled?
Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.. Recalled by Hikma Pharmaceuticals USA Inc.. Units affected: 97,890 vials.
Why was this product recalled?
Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 2, 2020. Severity: Moderate. Recall number: D-1533-2020.